報價延遲最少15分鐘:2025/06/02 07:30 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8385 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.06/-0.43
|
|
企業價值
11.46M
|
| 資產負債 |
|
每股賬面淨值
0.87
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for thetreatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). |